{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"17","upperLimit":"36","value":"22.5"}]}],"title":"More than 20 x 10^9/L"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"17","upperLimit":"46","value":"23"}]}],"title":"More than 50 x 10^9/L"}],"denoms":[{"counts":[{"groupId":"OG000","value":"8"}],"units":"Participants"}],"description":"Time to platelet engraftment is defined as the duration between Day 0 to the first day of platelet count sustained at \\> 20x109/L without transfusion. The median time to neutrophil and platelet engraftment will be reported.","dispersionType":"Full Range","groups":[{"description":"Bortezomib IV or SC (1.3mg/m2) on Days -6, -3, +1 and +4 Carmustine IV (300mg/m2) on Day -7 Etoposide IV twice daily (100 mg/m2) on Days -6, -5, -4, and -3 Cytarabine IV twice daily (100 mg/m2) on Days -6, -5, -4, and -3 Melphalan IV (140 mg/m2) on Day-2 Stem cell infusion on Day 0","id":"OG000","title":"V-BEAM + Stem Cell Infusion"}],"paramType":"MEDIAN","populationDescription":"Two participants without evaluable responses due to early mortality were not included in this analysis.","reportingStatus":"POSTED","timeFrame":"Day +100","title":"Time to Platelet Engraftment After V-BEAM.","type":"SECONDARY","unitOfMeasure":"days"}